| Related Articles |
Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan.
N Engl J Med. 2015 Dec 3;373(23):2289-2290
Authors: Claggett B, Packer M, McMurray JJ, Swedberg K, Rouleau J, Zile MR, Jhund P, Lefkowitz M, Shi V, Solomon SD, PARADIGM-HF Investigators
Abstract
Using actuarial data based on the results of the PARADIGM-HF trial, investigators found that the use of sacubitril-valsartan in patients with heart failure resulted in a mean of 1 to 2 additional years of survival, as compared with enalapril.
PMID: 26630151 [PubMed - as supplied by publisher]